Kymera Therapeutics, Inc.

This study is testing a new oral medication, KT-621, for people with moderate to severe atopic dermatitis (eczema). For 16 weeks, some participants will receive the drug while others get a placebo, followed by a year where everyone can receive the active treatment. The main goals…

This study is testing a new oral medication called KT-621 for adults with a specific type of moderate-to-severe asthma that remains uncontrolled despite using standard high-dose inhaler medications. Researchers aim to see if the pill improves lung function and asthma control whil…

This is the very first study giving a new oral medication called KT-579 to people. The main goal is to check if it is safe and how the body processes it. The study will involve about 96 healthy adult volunteers who will take either the drug or a placebo. Researchers will carefull…